Sandoz to invest in Ljubljana drug-substance facility to expand biosimilar capacity
Sandoz Group AG plans to invest in a new drug-substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.